Clinical trial
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632
Study timeline
Study start (actual)2020-06-08Date precision: day
Registry last updated2026-07-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small Cell Lungunresolved
Squamous Cell Carcinoma of Head and Neckunresolved
HER2 Negative Breast Neoplasmsunresolved
Esophageal Squamous Cell Carcinomaunresolved
Esophageal Adenocarcinomaunresolved
Gastroesophageal Junction Adenocarcinomaunresolved
Ovarian Neoplasmsunresolved
Cutaneous Squamous Cell Cancerunresolved
Exocrine Pancreatic Adenocarcinomaunresolved
Urinary Bladder Neoplasmsunresolved
Uterine Cervical Neoplasmsunresolved
Stomach Neoplasmsunresolved
Interventions
pembrolizumabDRUG · verified · RxNorm: pembrolizumab
cisplatinDRUG · verified · RxNorm: cisplatin
carboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
Seagen, a wholly owned subsidiary of Pfizerlead sponsor
Mapped research locations
SpringfieldIllinois, United States7MadridSpain6BostonMassachusetts, United States5BarcelonaSpain5LondonUnited Kingdom5SeoulSouth Korea4PortlandOregon, United States4IndianapolisIndiana, United States4Kansas CityKansas, United States4HoustonTexas, United States3ChicagoIllinois, United States3Los AngelesCalifornia, United States3
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04389632 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.